The biological diagnosis of Pneumocystis jirovecii pneumonia (PjP) is based on the investigation of respiratory fluids by conventional staining methods and/or molecular biology. Diagnostic performance of an in-house technique based on calcofluor-blue brightener for the direct detection of P. jirovecii cysts was prospectively assessed in bronchial-alveolar lavage fluids (BALF) from patients with a suspected PjP infection over a three-year period in a single center: the diagnostic yield was compared to that of a commercial kit based on monoclonal immunofluorescence assay (IFA) on replicate smears. May-Grünwald Giemsa (MGG) staining and quantitative Polymerase Chain Reaction (qPCR) were also performed. The gold standard for each patient was the definitive diagnosis of PjP infection by an independent committee based on clinical, radiological, and biological data. Overall, 481 BALF were assessed: 42 were found to be positive for the detection of P. jirovecii by at least one laboratory technique, but only 35 were actually judged to be in agreement with the definitive diagnosis of PjP infection. The sensitivity of the calcofluorblue brightener technique was 74.3% vs. 60.0%, 34.6%, and 82.9% for IFA, MGG, and qPCR, respectively; and its specificity was 99.6% vs. 99.3%, 100.0%, and 99.4% for IFA, MGG, and qPCR. No technique was shown to be statistically superior to calcofluor-blue brightener. Further validation of the test through multicenter studies is now required, but in light of its low cost and easy preparation, the use of calcofluor-blue brightener in C The
Introduction
Pneumocystis jirovecii is an airborne fungus which is responsible for interstitial pneumonia. [1] [2] [3] Pneumocystis jirovecii pneumonia (PjP, formerly PCP) infection occurs mostly in immunocompromised patients, such as subjects infected with HIV (human immunodeficiency virus) or those with hematological malignancies, 4, 5 as well as other distinct populations that have been recently described. 6, 7 The biological diagnosis of PjP must be obtained by direct observation of the fungus and/or detection of its DNA within respiratory fluids, such as bronchial-alveolar lavage fluids (BALFs), 2, 8, 9 because P. jirovecii is not easy to grow in vitro. 10 These diagnostic procedures are not easy to perform by relatively inexperienced labs. For example, the historical staining method for direct detection, May-Grünwald Giemsa (MGG), has a low sensitivity, and others are difficult to handle due to their carcinogenicity, such as Gomori methenamine-silver (GMS) impregnation. 11 Furthermore, commercial kits that allow detection of P. jirovecii cysts using monoclonal and fluorescent-conjugated antibodies (immunofluorescent assay [IFA] ) are expensive. 12 Polymerase chain reaction (PCR) appears to be a powerful tool but is not feasible in daily routine in all laboratories. 11 In addition, PCR is currently not able to provide a definitive diagnosis in less than two hours. This corresponds to the duration of a real-time quantitative PCR (qPCR) run, which can be an important limitation in extremely urgent cases. Moreover, the cut-off value of the fungal burden (expressed in Cq [quantitative cycles]) of qPCR or the number of trophic form equivalents per ml (TFEq/ml) to distinguish between P. jirovecii colonization and a true PjP infection is still debatable. 9 There are surrogate biomarkers such as the measurement of β-D-glucan in blood, but they lack specificity when used alone. 13 Alternative diagnostic approaches for PjP diagnosis are still required. Fluorescent brighteners such as calcofluor may offer an easy-to-use solution. These agents are already well-known for enabling selective fluorescence staining of the cell wall of yeast or filamentous fungi, but their utility for PjP diagnosis has been far less investigated. 8, 12 We prospectively assessed an in-house method using calcofluorblue brightener to detect P. jirovecii cysts in patient BALF samples over a three-year period. We systematically compared the results with those obtained using the commercial detection kit based on monoclonal antibodies (IFA), and those obtained using conventional techniques, such as MGG staining and qPCR.
Material and methods

Study population
This study was prospectively performed in a French teaching hospital (2,008 inpatient beds) over a three-year period [Feb 2010 -Dec 2012 . All surgical and specialty units required for complete hospitalization are represented on site. We systematically included all BALFs that were collected, under routine medical practice, from patients with a suspected PjP infection, regardless of their demographics. Noninclusion criteria were: below 15 years old, and/or the lack of sufficient harvested BALF for the necessary investigations.
Comparison of the diagnostic techniques based on fluorescence
In-house method of direct detection of P. jirovecii cysts by calcofluor-blue brightener Each BALF was processed as follows: after centrifugation (1730 × g, 10 min), the pellet was resuspended in 10 ml 0.9% saline and recentrifuged. The supernatant was then discarded. This operation was repeated once. Then, 20 μl of the pellet was spotted onto a glass slide. The slides were fixed in methanol for 10 min. The slides were then placed in contact with 0.2% calcofluor-blue brightener (Fluorescent Brightener 28 R , Sigma, Saint-Louis, MO, USA) solution for 10 min. The calcofluor solution was prepared by mixing 0.1 g powder with 100 ml distilled water until completely dissolved and then mixed with an equal volume of a 1% suspension of Evans blue (Evans blue 50g R , MP Biomedicals, Illkirch-Graffenstaden, France). Each slide was read independently of the other below mentioned techniques under a Nikon Eclipse 80i R microscope (Nikon, Champignysur-Marne, France) using a 50× objective and excitation at 510-560 nm. A second reading by another microbiologist was systematically carried out. If a positive result was obtained, the P. jirovecii cysts were counted with the aid of a 100× objective.
Commercial method of indirect detection of P. jirovecii cysts by monoclonal antibody and FITC-conjugate
The initial preparation of the slides was strictly the same as described for calcofluor-blue fluorescence, and they were prepared at the same time. The slides were subsequently processed according to the procedure recommended by the manufacturer of the MonoFluo TM Pneumocystis jirovecii IFA test kit R (Bio-Rad, Marnes-la-Coquette, France): enzymatic digestion for 30 min was followed by two successive incubations with the murine monoclonal antibody, and then the FITC-conjugated anti-mouse antibody for 15 min each. Each slide was read twice using a 50× objective, with excitation at 465-495 nm. If a positive result was obtained, the P. jirovecii cysts were counted. According to the manufacturer, the positive cut off value is five cysts per slide. For this study, we considered every sample that had at least one cyst to be positive.
Comparison with additional diagnostic techniques
Conventional direct detection of P. jirovecii cysts and trophozoites by MGG staining For this technique, 100 μl of native BALF were deposited into a Cytofunnel double R device (Thermo Fisher Scientific, Asnières, France) for Cytospin3 R (Thermo Scientific Shandon, Illkirch, France) centrifugation (80 × g, 5 min) and then stained using MGG (Microscopy Hemacolor R , Millipore, Billerica, MA, USA). The two colored spots on each slide were microscopically read by a senior microbiologist and a lab technician. A magnification of 1000× was used to search for P. jirovecii cysts and trophozoites.
Detection of P. jirovecii DNA by Polymerase Chain Reaction
BALFs were systematically assayed for P. jirovecii repeated large subunit (mtLSU) rDNA by qPCR. The DNA was extracted from 200 μl of the BALF pellet (after centrifugation, 1730 × g, 10 min). The pellet was first incubated in 10 μl lyticase 1 IU/μl for 10 min at 37
• C. The DNA was then extracted using the QiAmpDNA Mini kit R (Qiagen, Courtaboeuf, France), according to the manufacturer's recommendations. Realtime qPCR was performed in a final volume of 25 μl using the GoTaq Probe qPCR Master mix R (Promega, Charbonnières-les-Bains, France) and 5 μl of each DNA extract. The following oligonucleotides were used: PJF1: 5 -CTGTTTCCCTTTCGACTATCTACCTT-3 and PJR1: 5 -CACTGAATATCTCGAGGGAGTATGAA-3 for the primers, and 5 -FAM-TCGCACATAGTCTGATTAT-MGB-3 for the specific TaqMan R probe. 9 The final concentrations of primers and probe were 0. Diagnostics, Liège, Belgium) and an endogenous in-house positive internal control (P. jirovecii DNA extract). The results were expressed in quantitative cycle (Cq) values and in trophic form equivalents per ml (TFEq/mL). TFEq/ml was calculated by extrapolation from a calibration curve giving the correspondence with Cq: each qPCR run comprised four serial ten-fold dilutions of a calibrated P. jirovecii DNA solution prepared from a suspension of P. jirovecii in which the trophic forms had been counted microscopically by two independent expert microbiologists. 9 Every sample with a positive Cq or TFEq/mL value was considered to be positive.
Assay performance and analysis
Since no standardized score is available so far to definitively classify individuals for the diagnosis of PjP, the final diagnosis of infection was systematically validated by physicians independent from the laboratory, based on agreement of the biological test results with clinical examination, supported by medical imaging. 1 In subjects with solid tumors, solid-organ transplant, or hematologic malignancies receiving long-term high-dose steroids and/or chemotherapy, the following criteria were systematically searched: subacute fever associated with hypoxemic and diffuse pulmonary involvement (e.g., bilateral infiltrates and/or ground-glass opacities and/or nodules and/or alveolar condensation on high-resolution computed tomography scan). 14 In HIVpositive patients were specifically screened the following data: resting oxygen saturation <90% and diffuse radiology shadowing (e.g., bilateral infiltrates and/or groundglass opacities and/or nodules and/or cystic changes on high-resolution computed tomography scan), as well as a history of anti-P. jirovecii primary prophylaxis. 15 For the whole population, were also studied microbiological recovery on respiratory samples and clinical outcome after 14 days of anti-P. jirovecii treatment. Epidemiological data were provided by the Service d'Information Médicale,Épidémiologie etÉconomie de la Santé, from Tours University Hospital.
Statistical analyses were performed using XLStat v.2014.6.04 R software (Addinsoft, Paris, France). Missing data (e.g., when the total volume of sample was insufficient to complete all the analyses) were managed by the method of mean imputation. A true positive for each laboratory technique was defined as a positive result that was in agreement with the definitive diagnosis of PjP infection. Diagnostic measures were calculated to assess performance: sensitivity (Se), specificity (Sp), predictive values (PPV and NPV), and likelihood ratios (+LR and −LR), as well as receiver operating characteristic (ROC) curves and their respective areas under the curve (AUC)
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Results
Study population
Overall, 502 BALF were prospectively addressed during the study period, but only 481 were analyzed, because five and 16 were excluded as they came from children and as their total volume was insufficient for investigation, respectively. Among them, 35 were collected from patients for whom the definitive diagnosis of PjP infection was subsequently made by the independent committee based on clinical presentation, medical imaging, and biological measures (overall estimated incidence of PjP infection: 2.21 episodes per 1,000 patient-days). Most of the cases involved immunocompromised males above 50 years of age with a mean count of 0.110 G/L CD 4 + lymphocytes at the time of diagnosis. Less than a quarter received anti-P. jirovecii chemoprophylaxis.
The demographical characteristics at baseline of the 35 infected patients are summarized in Table 1 .
Diagnostic performance
The results are summarized in Table 2 .
Overall, 42 BALF of the 481 samples were found to be positive by at least one technique. For two samples, qPCR had not been performed because volume was insufficient, and therefore their relative data were managed by mean imputation. All tested laboratory methods had high specificity. Only seven of the BALF were considered to be false-positives: one was due to non-specific detection with the MonoFluo TM Pneumocystis jirovecii IFA test kit R , and six showed qPCR results with Cq ≥ 40 cycles, generally consistent with P. jirovecii colonization. Two of these were also positive by the calcofluor-blue brightener method, but the independent committee excluded the likelihood of PjP infection.
The sensitivity appeared to be higher for qPCR, but calcofluor brightener was not statistically inferior (82.9% vs. 74.3%; P = .55). The number of P. jirovecii cysts determined using the calcofluor-blue brightener technique did not significantly correlate with the qPCR Cq (Spearman's rank correlation coefficient r = 0.312; P = .07) or TFEq/ml value (Spearman's rank correlation coefficient r = 0.007; P = .97).
The calcofluor-blue brightener-based method was 2-fold more sensitive than MGG staining (P < .001). There was no significant difference between calcofluor brightener and the MonoFluo TM Pneumocystis jirovecii IFA test kit R for positive sample detection (P = .07; AUC = 0.870 vs. 0.798, respectively (Mat suppl. 1A)). However, it was more convenient to recognize and count the cysts when using the calcofluor-blue brightener-based method ( Figure 1 ): this allowed the visualization of more P. jirovecii cysts in 96.3% of cases, although there was a statistical correlation between the results of the two techniques (Spearman's rank correlation coefficient = 0 .579; P < .001). The mean number of cysts that we were able to count using the calcofluor-blue brightener was 430 per glass slide (SD, 280) vs. 127 (SD, 93) using the commercial IFA kit (P < .0001; median = 9 vs. 2; interquartile range = 389 vs. 71, respectively) (Mat suppl. 1B).
Discussion
Pneumocystis jirovecii pneumonia (PjP, formerly PCP) is a fungal infection with possibly severe consequences [1] [2] [3] : mortality rates are still estimated to be around 20%. 17 Accurate and rapid diagnosis would allow rapid and effective treatment, reducing complications. 18 Fluorescent brighteners, such as calcofluor, are inexpensive reagents that have been widely used for a long time to microscopically visualize yeast and filamentous fungi in clinical samples. 19 P. jirovecii is assumed to become fluorescent when impregnated with calcofluor brighteners, as it is classified as a fungus. 2 Very few thorough studies have tested their utility for PjP diagnosis in BALF. 8 We thus
prospectively assessed the diagnostic performance of an inhouse direct detection method based on calcofluor-blue fluorescence for the detection of P. jirovecii in BALF over a three-year period. Almost 500 respiratory specimens were analyzed, even though our study was carried out in a single center. All collected BALFs were systematically and blindly studied. The calcofluor-blue technique was compared to a commercial kit under the same conditions of slide preparation and reading. MGG staining and real-time qPCR were also systematically performed to confirm or invalidate the biological diagnosis based on clinical and radiological findings. 9 The detection of P. jirovecii using calcofluor-blue brightener exhibited several benefits for the diagnosis of PjP infection. The technique was easy to implement and the slides easy to read. The P. jirovecii cysts were clearly identifiable with calcofluor-blue brightener and easy to distinguish from artefactual fluorescence making them easy to identify by microbiologists, even nonexperts, allowing their accurate counting. Thus, the observation of a single cyst is sufficient to score a sample as positive, eliminating the need to set a cutoff value, unlike for commercial kits. In addition, a larger number of P. jirovecii cysts were detected using calcofluorblue brightener, even though there was good agreement of the overall results with the commercial IFA kit. This finding may be particularly useful in cases of low fungal burden. Furthermore, the commercial IFA kit only allows detection of P. jirovecii cysts by means of its monoclonal antibody, whereas calcofluor-blue brightener enables alternative microbiological diagnoses, as it is able to bind to chitin of other fungi and microsporidia. 19 The average time required from preparation to reading was approximately 40 min, whereas the commercial IFA kit required 1 h 30 min because of incubation times for enzyme digestion and binding of the anti-P. jirovecii monoclonal and FITC-conjugated antibodies. The cost-effectiveness of the test is very high: 242€ for 5 g of calcofluor powder which is theoretically sufficient for several years' worth of tests, whereas 24 tests of the MonoFluo TM Pneumocystis jirovecii IFA test kit R cost 520€. Calcofluor-blue brightener does not impregnate P. jirovecii trophozoite forms, but was nevertheless more sensitive than MGG staining which is theoretically able to detect both trophozoites and cysts. 8, 11 In addition, although qPCR appeared highly sensitive and specific as previously reported, 20 detection by calcofluor-blue brightener was not shown to be statistically inferior to qPCR, maybe because of a default of power in our study. It was even positive in four cases of definitive PjP infection for which qPCR was negative: one was inhibited (and stayed inhibited in spite of subsequent dilution), and the other three samples were from patients that were already being given cotrimoxazole at the time of the bronchoscopy, since the radio-clinical presentation alone was judged sufficiently evocative to initiate treatment at the outset. Anti-P. jirovecii therapy may rapidly disable detection by qPCR, whereas visualization of cysts by calcofluor-blue brightener remains possible as this reagent binds to the chitin skeleton of the fungus, regardless of their viability. Based on our findings, we have modified our global diagnostic strategy for the detection of P. jirovecii in BALF samples in our medical department. In cases of high probability of a PjP infection, we now only perform MGG staining (which allows detection of other pathogens in BALF, such as Toxoplasma gondii tachyzoites) and calcofluor-blue brightener impregnation in the first-line. We no longer use the MonoFluo TM Pneumocystis jirovecii IFA test kit R in our facility as its sensitivity appeared to be lower than in previous studies, 21 whereas qPCR is only performed for suspicious or unclear situations, or when the BALF is of too poor quality to complete a reliable microscopic observation.
In the near future, larger studies could focus on alternative respiratory fluids, such as sputa, which are easier to collect, to assess the potential utility of calcofluor brightener in detecting P. jirovecii cysts in superficial samples. 22 However, according to our experience based on sporadic assays, only BALF seems to be sufficiently reliable for this purpose.
In conclusion, the routine use of calcofluor-blue brightener would allow for faster and less costly first-line biological diagnosis of PjP infection: pending further validation through wide multicenter studies, its features make it highly suitable for all clinical laboratories, including those in developing countries with limited technical resources. 23 
